Home > Healthcare > Pharmaceuticals > Finished Drug Form > Aminophylline Market

Aminophylline Market Size

Report ID: GMI9210
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Aminophylline Market Size

Aminophylline Market size was valued at USD 291.2 million in 2023 and is estimated to grow at 2.1% CAGR from 2024 to 2032. The market is primarily driven by its widespread use in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and several other respiratory diseases.

To get key market trends

Download Free Sample

According to the World Health Organization (WHO) data, respiratory diseases as a major cause of death. Similarly, an article in the Economic Times in 2023 highlighted a worldwide increase in asthma cases, affecting around 339 million individuals. While asthma can affect people of any age, it's more common in children. These observations highlighted the need for asthma therapeutics in alleviating the rising respiratory disease burden. Therefore, usage of aminophylline plays a crucial role in both treatment and diagnosis for those affected, thereby propelling market growth.

Aminophylline Market Report Attributes
Report Attribute	Details
Base Year:	2023
Aminophylline Market Size in 2023:	USD 291.2 Million
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	2.1%
2032 Value Projection:	USD 350.2 Million
Historical Data for:	2021 - 2023
No. of Pages:	150
Tables, Charts & Figures:	277
Segments covered:	Dosage Form, Medication Type, Application, Distribution Channel and Region
Growth Drivers:	Rising prevalence of respiratory diseases Growing government approvals and funding Expanding elderly demographic Growing advancement in the drug delivery system
Pitfalls & Challenges:	Availability of alternative therapeutic options Side effects and safety concerns

Learn more about the key segments shaping this market

Download Free Sample

Aminophylline is a medication primarily employed in managing respiratory disorders like asthma, COPD, and other associated respiratory ailments. It falls under the category of medications termed methylxanthines, acting by relaxing the muscles in the airways. Aminophylline is often administered orally or intravenously and is considered a bronchodilator with both short-term and long-term therapeutic effects.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Aminophylline market size was USD 291.2 million in 2023 and is expected to register 2.1% CAGR from 2024-2032 owing to its widespread use in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and several other respiratory diseases.

Aminophylline industry from the injection segment recorded USD 166.3 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to offering a rapid onset of action and precise dosing, making them preferred in acute situations such as severe asthma exacerbations.

The U.S. aminophylline industry held 92.1% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to growing respiratory disease condition, rising precision medicine and patient-centric therapies in the country.

Cipla, Cooper S.A., GSK plc, Glenmark Pharmaceuticals Ltd., Inopha International Co, Limited, Johnson & Johnson Pvt. Ltd., Lupin, Pfizer Inc., S.A.L.F. S.p.A. Laboratorio Farmacologico, Teva Pharmaceuticals Industries Ltd., are some of the major aminophylline companies worldwide.